← Metformin × adverse events & safety

TrialCancer prevention research (Philadelphia, Pa.)2015

Metformin use and risk of prostate cancer: results from the REDUCE study.

Tom Feng et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with higher adverse events & safety

+19%

Bigger than 5 in 10 for adverse events & safety

As reported

OR 1.19, no interval

Correlation, not cause

Went with higher adverse events & safety

+1%

Smaller than almost all for adverse events & safety

As reported

OR 1.01, no interval

Correlation, not cause

Went with higher adverse events & safety

+83%

Bigger than 8 in 10 for adverse events & safety

As reported

OR 1.83, no interval

+2 more in the walkthrough ↓

Five numbers in the abstract

the abstract, start to end

… significantly associated with total (OR, 1.19; P = 0.50), low- (OR, 1.01; P = 0.96), or high-grade (OR, 1.83; P = 0.19) prostate cancer …

… prostate cancer risk in both crude (OR, 1.02; P = 0.95) and multivariable analysis (OR, 0.85; P = 0.56).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Adverse events & safety
OR 1.19
Adverse events & safety
OR 1.01
Adverse events & safety
OR 1.83
Glycemic control
OR 1.02
Glycemic control
OR 0.85
MetforminOther glucose-loweringGlycemic controlAdverse events & safety
1 / 3

14 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 26353947